Literature DB >> 22322824

Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry.

Paola Pecchini1, Fabio Malberti, Maren Mieth, Robert Quinn, Giovanni Tripepi, Francesca Mallamaci, Renke Maas, Carmine Zoccali, Pietro Ravani.   

Abstract

BACKGROUND: Asymmetric dimethylarginine (ADMA) is increasingly being investigated as a renal and cardiovascular risk factor in chronic kidney disease (CKD). We assessed the degree of agreement of an enzyme-linked immunosorbent assay (ELISA) of ADMA and the gold standard liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS).
METHODS: ADMA was measured in an incident cohort of 126 stable CKD patients. Correlations between methods were studied by estimating the interclass Pearson coefficient (IPC), Lin's concordance correlation coefficient (CCC) and the maximum likelihood intraclass correlation coefficient (ICC). Limits of agreement (LOA) were estimated using the Bland-Altman method.
RESULTS: ADMA values were normally distributed with means of 0.78 ± 0.16 (ELISA) and 0.59 ± 0.09 mol/L (LC-MS/MS). IPC was 0.69 (95% confidence interval [95% CI], 0.59-0.78). Overall CCC was 0.29 (95% CI, 0.23-0.37), with a difference in means of 0.19 mol/L (95% LOA, -0.043 to 0.43), delta slope of 0.577 and delta intercept of 0.14 (vs. perfect agreement line). Data were similar across categories of clinical characteristics. Mixed models provided an ICC of 0.58 (95% CI, 0.46-0.69). Bias was larger among patients with glomerular filtration rate (GFR) <30 ml/min. When values obtained from ELISA were corrected using the slope and intercept estimates from concordance analyses, the adjusted ICC improved to 0.67 (95% CI, 0.57-0.76), and bias modification by GFR levels canceled out.
CONCLUSIONS: In CKD, ELISA overestimates ADMA concentration as compared with LC-MS/MS. Appropriate calibration is needed when ADMA is measured by ELISA in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322824     DOI: 10.5301/jn.5000085

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  5 in total

1.  Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.

Authors:  Giovanni Tripepi; Barbara Kollerits; Daniela Leonardis; Mahamut Ilker Yilmaz; Maurizio Postorino; Danilo Fliser; Francesca Mallamaci; Florian Kronenberg; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2014-08-22       Impact factor: 10.121

2.  Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy.

Authors:  Zoltan Nemeth; Attila Cziraki; Sandor Szabados; Bernadett Biri; Sandor Keki; Akos Koller
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

Review 3.  Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases.

Authors:  Mustafa E Sitar
Journal:  Biomark Insights       Date:  2016-12-07

4.  Response to Tsikas et al. Comments on Boelaert et al. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Toxins 2016, 8, 149.

Authors:  Jente Boelaert; Eva Schepers; Griet Glorieux; Sunny Eloot; Raymond Vanholder; Frédéric Lynen
Journal:  Toxins (Basel)       Date:  2016-10-27       Impact factor: 4.546

5.  Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Authors:  Jente Boelaert; Eva Schepers; Griet Glorieux; Sunny Eloot; Raymond Vanholder; Frédéric Lynen
Journal:  Toxins (Basel)       Date:  2016-05-13       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.